{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T13:56:54Z","timestamp":1762005414890,"version":"3.41.0"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,6]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>Autosomal dominant polycystic kidney disease (ADPKD) is less common than primary hypertension or diabetes but should be considered as a possible cause of end-stage renal disease, especially in young patients without comorbidities. Because of ADPKD's nonspecific symptoms, the diagnosis, treatment, and pertinent patient education may be delayed. This article describes ADPKD and its management, including tolvaptan, a new treatment with the potential to reduce or delay morbidity. However, only a subset of patients qualifies for this expensive treatment.<\/jats:p>","DOI":"10.1097\/01.jaa.0000931420.46207.82","type":"journal-article","created":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T08:28:34Z","timestamp":1683793714000},"page":"11-16","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["An update on treatments for autosomal dominant polycystic kidney disease"],"prefix":"10.1097","volume":"36","author":[{"given":"Suhani Janak","family":"Patel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine K.","family":"Sadowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"issue":"12","key":"R1-20250605","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1002\/humu.22708","article-title":"Genetics and pathogenesis of autosomal dominant polycystic kidney disease: 20 years on","volume":"35","author":"Cornec-Le Gall","year":"2014","journal-title":"Hum Mutat"},{"issue":"10","key":"R2-20250605","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1681\/ASN.2018050493","article-title":"Prevalence estimates of polycystic kidney and liver disease by population sequencing","volume":"29","author":"Lanktree","year":"2018","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"R3-20250605","doi-asserted-by":"crossref","first-page":"100887","DOI":"10.1016\/j.disamonth.2019.100887","article-title":"Update and review of adult polycystic kidney disease","volume":"66","author":"Colbert","year":"2020","journal-title":"Dis Mon"},{"issue":"5","key":"R4-20250605","first-page":"303","article-title":"Autosomal dominant polycystic kidney disease","volume":"90","author":"Srivastava","year":"2014","journal-title":"Am Fam Physician"},{"issue":"4 suppl 1","key":"R5-20250605","doi-asserted-by":"crossref","first-page":"A7","DOI":"10.1053\/j.ajkd.2021.01.002","article-title":"US Renal Data System 2020 Annual Data Report: epidemiology of kidney disease in the United States","volume":"77","author":"Johansen","year":"2021","journal-title":"Am J Kidney Dis"},{"issue":"10174","key":"R6-20250605","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S0140-6736(18)32782-X","article-title":"Autosomal dominant polycystic kidney disease","volume":"393","author":"Cornec-Le Gall","year":"2019","journal-title":"Lancet"},{"issue":"24","key":"R7-20250605","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1402685","article-title":"Blood pressure in early autosomal dominant polycystic kidney disease","volume":"371","author":"Schrier","year":"2014","journal-title":"N Engl J Med"},{"issue":"25","key":"R8-20250605","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","article-title":"Tolvaptan in patients with autosomal dominant polycystic kidney disease","volume":"367","author":"Torres","year":"2012","journal-title":"N Engl J Med"},{"issue":"20","key":"R9-20250605","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1056\/NEJMoa1710030","article-title":"Tolvaptan in later-stage autosomal dominant polycystic kidney disease","volume":"377","author":"Torres","year":"2017","journal-title":"N Engl J Med"},{"issue":"10","key":"R10-20250605","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1681\/ASN.2018060590","article-title":"A practical guide for treatment of rapidly progressive ADPKD with tolvaptan","volume":"29","author":"Chebib","year":"2018","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"R11-20250605","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1681\/ASN.2017050483","article-title":"Genetic complexity of autosomal dominant polycystic kidney and liver diseases","volume":"29","author":"Cornec-Le Gall","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"R13-20250605","first-page":"69","article-title":"Polycystic kidney disease: inheritance, pathophysiology, prognosis, and treatment","volume":"3","author":"Halvorson","year":"2010","journal-title":"Int J Nephrol Renovasc Dis"},{"issue":"2","key":"R14-20250605","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1093\/ndt\/gft437","article-title":"Extra-renal manifestations of autosomal dominant polycystic kidney disease (ADPKD): considerations for routine screening and management","volume":"29","author":"Luciano","year":"2014","journal-title":"Nephrol Dial Transplant"},{"issue":"6","key":"R15-20250605","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1148\/rg.306105513","article-title":"Adult renal cystic disease: a genetic, biological, and developmental primer","volume":"30","author":"Katabathina","year":"2010","journal-title":"RadioGraphics"},{"issue":"6","key":"R16-20250605","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/j.ajhg.2016.05.004","article-title":"Mutations in GANAB, encoding the glucosidase IIa subunit, cause autosomal-dominant polycystic kidney and liver disease","volume":"98","author":"Porath","year":"2016","journal-title":"Am J Hum Genet"},{"issue":"5","key":"R17-20250605","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.ajhg.2018.03.013","article-title":"Monoallelic mutations to DNAJB11 cause atypical autosomal-dominant polycystic kidney disease","volume":"102","author":"Cornec-Le Gall","year":"2018","journal-title":"Am J Hum Genet"},{"issue":"4","key":"R18-20250605","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/ki.2015.28","article-title":"Autosomal dominant tubulointerstitial kidney disease: diagnosis, classification, and management\u2014a KDIGO consensus report","volume":"88","author":"Eckardt","year":"2015","journal-title":"Kidney Int"},{"issue":"6","key":"R19-20250605","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1681\/ASN.2012070650","article-title":"Type of PKD1 mutation influences renal outcome in ADPKD","volume":"24","author":"Cornec-Le Gall","year":"2013","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"R20-20250605","doi-asserted-by":"crossref","first-page":"479","DOI":"10.2215\/CJN.09500911","article-title":"Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease","volume":"7","author":"Chapman","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"R21-20250605","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1681\/ASN.2015010016","article-title":"The PROPKD score: a new algorithm to predict renal survival in autosomal dominant polycystic kidney disease","volume":"27","author":"Cornec-Le Gall","year":"2016","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"R22-20250605","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1093\/ndt\/gfab312","article-title":"An update on the use of tolvaptan for autosomal dominant polycystic kidney disease: consensus statement on behalf of the ERA Working Group on Inherited Kidney Disorders, the European Rare Kidney Disease Reference Network and Polycystic Kidney Disease International","volume":"37","author":"M\u00fcller","year":"2022","journal-title":"Nephrol Dial Transplant"},{"issue":"6","key":"R24-20250605","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.semnephrol.2015.10.008","article-title":"KHA-CARI autosomal dominant polycystic kidney disease guideline: diet and lifestyle management","volume":"35","author":"Campbell","year":"2015","journal-title":"Semin Nephrol"},{"key":"R25-20250605","doi-asserted-by":"crossref","first-page":"12816","DOI":"10.1038\/srep12816","article-title":"Comparative study of outcomes among patients with polycystic kidney disease on hemodialysis and peritoneal dialysis","volume":"5","author":"Yang","year":"2015","journal-title":"Sci Rep"},{"issue":"3","key":"R26-20250605","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s40265-019-1056-1","article-title":"Tolvaptan: a review in autosomal dominant polycystic kidney disease","volume":"79","author":"Blair","year":"2019","journal-title":"Drugs"},{"issue":"6","key":"R27-20250605","doi-asserted-by":"crossref","first-page":"382","DOI":"10.7326\/0003-4819-159-6-201309170-00004","article-title":"Cost-effectiveness of tolvaptan in autosomal dominant polycystic kidney disease","volume":"159","author":"Erickson","year":"2013","journal-title":"Ann Intern Med"}],"container-title":["JAAPA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/01.JAA.0000931420.46207.82","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T20:02:11Z","timestamp":1749153731000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/01.JAA.0000931420.46207.82"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/01.jaa.0000931420.46207.82","relation":{},"ISSN":["1547-1896"],"issn-type":[{"type":"print","value":"1547-1896"}],"subject":[],"published":{"date-parts":[[2023,6]]}}}